Table 1.
Detailed clinicopathological characteristics of the patient population
| Sample ID | Age | Gender | Liver Disease | Serum Analysis | Urine analysis | Any known kidney disease | Anti-viral therapy | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HBV viral load category | HBV viral Load (IU/mL) | HBeAg (+/−) | HBsAg (+/−) | AST (IU/L) | ALT (IU/L) | AFP (ng/ml) | RBC/ High power field | Urine albumin (mg/dL) | ||||||
| 1 | 29 | F | Cirrhosis | High | 1.70E + 08 | + | + | 44 | 36 | < 1.3 | 2~ 5 | 30 | – | No |
| 2 | 36 | F | CHB | High | 1.70E + 08 | + | + | 20 | 17 | 1.7 | 0 | – | CKD | No |
| 3 | 32 | M | CHB | High | 1.70E + 08 | + | + | 33 | 64 | 1.3 | 0~ 2 | – | – | No |
| 4 | 41 | F | Cirrhosis | High | 1.34E + 08 | + | + | 191 | 126 | 5.8 | 2~ 5 | – | – | Yes |
| 5 | 52 | F | CHB | High | 6.07E + 07 | + | + | 23 | 21 | 4 | 0~ 2 | 10 | FSGS,CGN | No |
| 6 | 52 | M | Cirrhosis | High | 5.81E + 07 | + | + | 109 | 48 | 81 | 0~ 2 | – | – | Yes |
| 7 | 68 | F | Cirrhosis | High | 4.57E + 07 | + | + | 73 | 38 | 3.6 | 2~ 5 | 200 | – | Yes |
| 8 | 29 | F | CHB | High | 4.53E + 07 | + | + | 48 | 60 | 1.8 | 0~ 2 | – | – | No |
| 9 | 32 | M | CHB | High | 4.13E + 07 | + | + | 394 | 921 | 16.4 | 0~ 2 | – | – | Yes |
| 10 | 22 | M | CHB | High | 3.04E + 07 | + | + | 160 | 556 | 5.2 | 0 | – | – | No |
| 11 | 54 | M | CHB | High | 1.44E + 07 | – | + | 24 | 25 | 2.8 | 0 | – | – | No |
| 12 | 72 | F | CHB | High | 3.89E + 06 | – | + | 58 | 62 | 35.1 | 0~ 2 | – | – | No |
| 13 | 59 | M | CHB | High | 1.78E + 06 | – | + | 69 | 97 | 4.3 | 0~ 2 | – | – | No |
| 14 | 65 | M | CHB | High | 1.37E + 06 | – | + | 60 | 110 | 5 | 0~ 2 | – | – | No |
| 15 | 60 | F | CHB | High | 8.30E + 05 | – | + | 171 | 242 | 2.8 | 0~ 2 | – | – | Yes |
| 16 | 42 | M | CHB | High | 7.47E + 05 | – | + | 22 | 24 | < 1.3 | 2~ 5 | – | – | Yes |
| 17 | 55 | F | CHB | High | 7.25E + 05 | + | + | 299 | 424 | 7.4 | 0~ 2 | – | – | Yes |
| 18 | 60 | M | Cirrhosis | High | 4.17E + 05 | – | + | 64 | 63 | 32.8 | 0~ 2 | – | – | No |
| 19 | 36 | M | CHB | High | 3.38E + 05 | + | + | 34 | 50 | 4.2 | 2~ 5 | 10 | – | Yes |
| 20 | 60 | F | CHB | High | 3.19E + 05 | – | + | 99 | 124 | 2.6 | 0~ 2 | – | – | No |
| 21 | 41 | M | CHB | High | 2.10E + 05 | – | + | 89 | 207 | 6.5 | 0 | – | – | No |
| 22 | 48 | M | CHB | High | 1.67E + 05 | – | + | 31 | 35 | < 1.3 | 0 | – | – | No |
| 23 | 63 | F | CHB | High | 1.48E + 05 | – | + | 43 | 30 | 1.9 | 0~ 2 | – | – | No |
| 24 | 65 | F | HCC | High | 1.08E + 05 | + | + | 186 | 95 | 2623.1 | 0~ 2 | – | – | No |
| 25 | 62 | M | CHB | High | 1.02E + 05 | – | + | 27 | 39 | 3.4 | 0~ 2 | – | – | No |
| 26 | 48 | F | CHB | Low | 9.31E + 04 | – | + | 28 | 31 | 3.3 | 0~ 2 | – | – | No |
| 27 | 46 | M | CHB | Low | 4.85E + 04 | – | + | 33 | 53 | 2.1 | 0 | – | – | No |
| 28 | 67 | F | CHB | Low | 3.93E + 04 | – | + | 38 | 27 | 5 | 0 | – | – | No |
| 29 | 52 | M | CHB | Low | 3.82E + 04 | – | + | 32 | 37 | 4.1 | 0~ 2 | – | – | No |
| 30 | 75 | F | CHB | Low | 2.75E + 04 | – | + | 41 | 30 | 3.4 | 2~ 5 | – | – | Yes |
| 31 | 31 | M | CHB | Low | 2.65E + 04 | + | + | 38 | 57 | < 1.3 | 0 | – | – | Yes |
| 32 | 44 | M | Cirrhosis | Low | 1.74E + 04 | + | + | 72 | 95 | 2.4 | > 100 | 70 | – | No |
| 33 | 48 | F | CHB | Low | 1.65E + 04 | – | + | 22 | 22 | < 1.3 | 0 | – | – | No |
| 34 | 54 | M | CHB | Low | 1.49E + 04 | – | + | 40 | 52 | < 1.3 | 0~ 2 | 10 | – | No |
| 35 | 51 | F | CHB | Low | 1.01E + 04 | – | + | 36 | 22 | 1.4 | 2~ 5 | – | NA | No |
| 36 | 48 | M | CHB | Low | 9.68E + 03 | – | + | 38 | 30 | 6.7 | 0~ 2 | 600 | – | No |
| 37 | 53 | F | CHB | Low | 6.40E + 03 | – | + | 46 | 81 | 2.1 | 0~ 2 | – | – | No |
| 38 | 59 | M | CHB | Low | 4.36E + 03 | – | + | 44 | 25 | 2.1 | 0~ 2 | – | – | Yes |
| 39 | 46 | M | CHB | Low | 4.08E + 03 | – | + | 27 | 35 | 5.2 | 0 | – | – | No |
| 40 | 18 | M | CHB | Low | 3.18E + 03 | + | + | 45 | 78 | 1.6 | 0~ 2 | 10 | – | No |
| 41 | 57 | M | CHB | Low | 3.00E + 03 | – | + | 29 | 38 | 3.5 | 0~ 2 | – | – | Yes |
| 42 | 57 | F | Cirrhosis | Low | 2.93E + 03 | – | + | 33 | 44 | 1.4 | 0~ 2 | – | – | No |
| 43 | 28 | M | CHB | Low | 2.68E + 03 | – | + | 35 | 48 | 21.4 | 0~ 2 | 30 | – | No |
| 44 | 47 | M | CHB | Low | 2.42E + 03 | – | + | 42 | 82 | 2.1 | 2~ 5 | 10 | – | No |
| 45 | 64 | F | CHB | Low | 2.24E + 03 | – | + | 58 | 67 | 3.9 | 0~ 2 | – | – | No |
| 46 | 58 | M | CHB | Low | 2.02E + 03 | – | + | 26 | 28 | < 1.3 | 0~ 2 | 20 | – | No |
| 47 | 43 | F | CHB | Low | 1.83E + 03 | – | – | 26 | 26 | 6.2 | 2~ 5 | – | – | No |
| 48 | 56 | F | CHB | Low | 1.50E + 03 | – | + | 26 | 23 | 2.4 | 0~ 2 | – | – | No |
| 49 | 33 | F | CHB | Low | 1.49E + 03 | – | + | 28 | 42 | 3.2 | 0~ 2 | – | – | No |
| 50 | 56 | F | CHB | Low | 1.25E + 03 | – | + | 34 | 67 | 2.6 | 2~ 5 | – | – | Yes |
| 51 | 38 | M | CHB | Low | 1.17E + 03 | – | + | 43 | 91 | 5 | 0~ 2 | – | – | No |
| 52 | 38 | M | CHB | Low | 1.09E + 03 | – | + | 38 | 77 | 2.4 | 0~ 2 | 10 | – | No |
| 53 | 61 | M | CHB | Low | 1.07E + 03 | – | + | 26 | 30 | 2.1 | 0~ 2 | – | – | No |
| 54 | 51 | M | CHB | Low | 1.06E + 03 | – | + | 21 | 27 | 2.8 | 0 | – | – | No |
| 55 | 28 | F | CHB | Low | 3.41E + 02 | – | + | 36 | 32 | 2.7 | 0~ 2 | – | – | Yes |
| 56 | 34 | M | CHB | Low | 5.40E + 01 | – | + | 32 | 53 | 2.4 | 0 | – | – | Yes |
| 57 | 36 | M | CHB | Low | 3.20E + 01 | + | + | 116 | 98 | 3.5 | 2~ 5 | 50 | – | Yes |
| 58 | 69 | M | HCC | Low | 2.00E + 01 | – | + | 45 | 21 | 5060.9 | > 100 | 30 | – | No |
| 59 | 40 | M | CHB | Low | 2.00E + 01 | – | – | 41 | 65 | 3.8 | 0 | – | – | Yes |
| 60 | 38 | M | CHB | Low | < 20 | – | + | 46 | 57 | 7.7 | 0~ 2 | – | – | Yes |
F female, M male, CHB Chronic hepatitis B infection, NA Data not available, CKD chronic kidney disease, FSGS focal segmental glomerulosclerosis, CGN chronic glomerulonephritis
For all patients who received antiviral treatment, the drug received was “Telbivudine,” which has no known renal side effects